CN116440222A - 一种抗菌美白的中药组合物 - Google Patents
一种抗菌美白的中药组合物 Download PDFInfo
- Publication number
- CN116440222A CN116440222A CN202310643014.4A CN202310643014A CN116440222A CN 116440222 A CN116440222 A CN 116440222A CN 202310643014 A CN202310643014 A CN 202310643014A CN 116440222 A CN116440222 A CN 116440222A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- traditional chinese
- chinese medicine
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000002087 whitening effect Effects 0.000 title claims abstract description 15
- 241000894006 Bacteria Species 0.000 title description 7
- 241001071795 Gentiana Species 0.000 claims abstract description 19
- 241001313857 Bletilla striata Species 0.000 claims abstract description 17
- 244000146462 Centella asiatica Species 0.000 claims abstract description 17
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 17
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 17
- 244000197580 Poria cocos Species 0.000 claims abstract description 17
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 17
- 235000020251 goat milk Nutrition 0.000 claims abstract description 16
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 15
- 240000003705 Senecio vulgaris Species 0.000 claims abstract description 12
- 230000009194 climbing Effects 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 239000008213 purified water Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241001598107 Imperata Species 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 238000009835 boiling Methods 0.000 claims description 16
- 241000563984 Ampelopsis Species 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 241000123835 Ampelopsis japonica Species 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 241001146210 Senecio scandens Species 0.000 claims description 5
- 241000217407 Margaritifera Species 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 241000283898 Ovis Species 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 206010000496 acne Diseases 0.000 abstract description 14
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 13
- 230000001815 facial effect Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 230000008591 skin barrier function Effects 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 230000037314 wound repair Effects 0.000 abstract description 2
- 240000007171 Imperata cylindrica Species 0.000 abstract 1
- 241000219099 Parthenocissus quinquefolia Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 229940126680 traditional chinese medicines Drugs 0.000 description 7
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000001382 Experimental Melanoma Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 235000020254 sheep milk Nutrition 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000008316 Arsenic Poisoning Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000166541 Plumeria alba Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及一种抗菌美白的中药组合物，所述中药组合物由10‑50重量份千里光、10‑50重量份龙胆草、10‑50重量份羊乳、10‑50重量份白蔹、10‑50重量份白芨、10‑50重量份积雪草、10‑50重量份茯苓、10‑50重量份薏苡仁、10‑50重量份珍珠母和10‑50重量份白茅根制备而成。本发明的中药组合物具有修复皮肤屏障、促进伤口修复的功效，对于改善面部痤疮、面部皮炎瘙痒和面部色斑暗沉具有显著疗效。
Description
技术领域
本发明涉及中药领域，具体涉及一种抗菌美白的中药组合物。
背景技术
痤疮是以黑白粉刺、丘疹、囊肿、瘢痕等皮损为主要临床表现，常伴有皮脂溢出，好发于面部、下颌部、前胸和后背，病情迁延不愈，反复发作。痤疮与嗜辛辣油腻食物、熬夜、环境压力等密切相关，另外免疫、遗传、化妆品使用不当均可成为痤疮的致病因素，女性患者还常在月经来潮前炎性物质分泌增多，皮损处愈加明显，痤疮加重。
西医治疗痤疮采用口服异维生A酸、糖皮质激素类，外涂克林霉素凝胶等或联合物理疗法治疗，这些治法能产生短暂性的疗效，无法彻底治愈痤疮，复发率极高，易产生依赖性和耐药性。此外，西药禁忌证偏多，适用人群有限，皮损处还会出现色素沉淀、“激光脸”等不良反应，甚至会损害肝肾功能。
中医将痤疮归为“面疱”、“肺风粉刺”的范畴。现有中药药理研究表明，中药可以杀灭痤疮丙酸杆菌，抑制皮脂腺分泌油脂，调节体内雌、雄激素水平，抗炎修复皮肤屏障，增强自身免疫力。此外，中药还能够直接作用于病变脏腑，清腑泄热，排瘀逐痰，解毒利湿，调理冲任使气机调达，阴阳平和，脏腑功能恢复正常，由内而外根治痤疮。
紫外线、作息等因素导致皮肤中黑色素增多聚集，致使面部色度降低影响形象。黑色素主要是由皮肤的表皮基底层的黑色素细胞生成，其生成机制为：位于黑色素细胞膜上的酪氨酸酶是一种具有双核铜离子的金属酶，在黑色素合成中起着限速酶的作用，可在正常生理或外界刺激如紫外线照射等条件下激活，黑色素细胞中的酪氨酸在酪氨酸酶的催化氧化作用下，经一系列转化生成褐色素及真黑素，两者统称为黑色素。根据黑色素的生成步骤，目前市面上美白产品的作用机制可归纳为抑制氧化反应发生、抑制酪氨酸酶的活性，或加快皮肤新陈代谢，使黑色素细胞向角质层转移并随着角质层更新脱落而达到美白的作用。
目前兼具良好抗菌和美白功效的中药组方报道较少，因此从中药领域进一步发掘应用于抗菌美白的药物已成为亟待解决的技术问题，研发具有抗菌美白功效的中药仍具有广阔的临床应用前景。
发明内容
为解决上述技术问题，本发明包括以下几个方面：
本发明的第一方面提供一种抗菌美白的中药组合物，所述中药组合物由千里光、龙胆草、羊乳、白蔹、白芨、积雪草、茯苓、薏苡仁、珍珠母和白茅根制备而成。
优选的，所述中药组合物由10-50重量份千里光、10-50重量份龙胆草、10-50重量份羊乳、10-50重量份白蔹、10-50重量份白芨、10-50重量份积雪草、10-50重量份茯苓、10-50重量份薏苡仁、10-50重量份珍珠母和10-50重量份白茅根制备而成。
更优选的，所述中药组合物由10-30重量份千里光、10-30重量份龙胆草、10-30重量份羊乳、10-30重量份白蔹、10-30重量份白芨、10-30重量份积雪草、10-30重量份茯苓、10-30重量份薏苡仁、10-30重量份珍珠母和10-30重量份白茅根制备而成。
进一步优选的，所述中药组合物由10-20重量份千里光、10-20重量份龙胆草、20-30重量份羊乳、20-30重量份白蔹、20-30重量份白芨、10-20重量份积雪草、20-30重量份茯苓、20-30重量份薏苡仁、20-30重量份珍珠母和10-20重量份白茅根制备而成。
最优选的，所述中药组合物由10重量份千里光、10重量份龙胆草、30重量份羊乳、30重量份白蔹、30重量份白芨、10重量份积雪草、30重量份茯苓、30重量份薏苡仁、30重量份珍珠母和15重量份白茅根制备而成。
优选的，所述中药组合物进一步包括药学上可接受的辅料。
优选的，所述中药组合物的剂型为液体制剂。
优选的，所述中药组合物为外用制剂。
更优选的，所述中药组合物的剂型为溶液剂、洗剂、酊剂或者搽剂。
优选的，所述中药组合物的制备方法包括以下步骤：
(1)称取处方量的千里光、龙胆草、羊乳、白蔹、白芨、积雪草、茯苓、薏苡仁、珍珠母和白茅根，将上述中药混合后加入中药材重量4-8倍的纯净水，浸泡15-60min，大火煮开后文火煎煮20-40min；
(2)将煎煮后的药液倒入容器中，药渣再加入4-6倍重量的纯净水，大火煮开后文火煎煮20-40min；
(3)将两次煎煮的药液合并，过滤，离心取上清液，浓缩，即得。
优选的，所述步骤(1)中加入中药材重量7倍的纯净水，浸泡30min，大火煮开后文火煎煮30min。
优选的，所述步骤(2)中药渣再加入5倍重量的纯净水，大火煮开后文火煎煮30min。
优选的，所述步骤(3)中将上清液浓缩成0.3-0.4g/mL的中药提取液。
本发明的第二方面是提供上述中药组合物的制备方法，所述制备方法包括以下步骤：
(1)称取处方量的千里光、龙胆草、羊乳、白蔹、白芨、积雪草、茯苓、薏苡仁、珍珠母和白茅根，将上述中药混合后加入中药材重量4-8倍的纯净水，浸泡15-60min，大火煮开后文火煎煮20-40min；
(2)将煎煮后的药液倒入容器中，药渣再加入4-6倍重量的纯净水，大火煮开后文火煎煮20-40min；
(3)将两次煎煮的药液合并，过滤，离心取上清液，浓缩，即得。
优选的，所述步骤(1)中加入中药材重量7倍的纯净水，浸泡30min，大火煮开后文火煎煮30min。
优选的，所述步骤(2)中药渣再加入5倍重量的纯净水，大火煮开后文火煎煮30min。
优选的，所述步骤(3)中将上清液浓缩成0.3-0.4g/mL的中药提取液。
本发明的第三方面是提供上述中药组合物在制备抗菌药物中的应用。
优选的，所述抗菌药物是治疗痤疮丙酸杆菌的药物。
优选的，本发明提供上述中药组合物在制备治疗痤疮的药物中的应用。
本发明的第四方面是提供上述中药组合物在制备具有美白功效的药物中的应用。
本发明的第五方面是提供上述中药组合物在制备降低血清中IL-1β和/或TNF-ɑ水平的药物中的应用。
本发明的第六方面是提供上述中药组合物在制备降低黑色素瘤细胞增殖率的药物中的应用。
本发明选用的中药原料在本领域的常见药理功效如下：
千里光：性寒，味苦，归肝经、肺经。千里光清热解毒、凉血消肿、清肝明目、杀虫止痛，用于治疗风热感冒、流行性感冒、上呼吸道感染、急性扁桃体炎、咽喉肿痛、肺炎、大叶性肺炎等。
龙胆草：又名龙胆，性寒，味苦，归肝经、胆经。龙胆草清肝火、除湿热、健胃，用于治疗目赤头晕、耳聋耳肿、胁痛口苦、咽喉肿痛、惊痫抽搐、湿热疮毒、湿疹、阴肿、阴痒、小便淋痛、食欲不振，具有保肝、利胆、健胃、抗炎及免疫、抗甲亢、抗菌、镇痛镇静等功效。
羊乳：又名奶树、四叶参，性甘、辛平，归肺、肝、脾、大肠经。羊乳败毒抗癌、补气养血、消肿排脓，用于治疗肺痈，乳痈，肠痈，肿毒，瘰疬，喉蛾，乳少，白带等。
白蔹：性微寒，味苦。归心经、胃经。白蔹清热解毒、消痈散结，用于治疗痈疽发背、疔疮、瘰疬、水火烫伤等。
白芨：又名白及，性微寒，味苦、甘、涩，归肺经、肝经、胃经。白芨收敛止血、消肿生肌，用于治疗外伤出血、疮疡肿毒、皮肤皲裂。
积雪草：性寒，味苦、辛，归肝经、脾经、肾经，具有清湿热、解毒消肿、活血利尿功效，属清热药下分类的清热燥湿药。临床用于治疗湿热黄疸、痈疮肿毒、跌打损伤、解砒霜中毒及蕈中毒、解暑。
茯苓：性平，味甘、淡，归心、肺、脾、肾经。茯苓利水渗湿，健脾，宁心，用于治疗水肿尿少，痰饮眩悸，脾虚食少，便溏泄泻，心神不安，惊悸失眠。
薏苡仁：性凉，味甘、淡，归脾、胃、肺经。薏苡仁利水渗湿，健脾止泻，除痹，排脓，解毒散结，用于治疗水肿，脚气，小便不利，脾虚泄泻，湿痹拘挛，肺痈，肠痈，赘疣。
珍珠母：性寒，味咸，归肝经、心经。珍珠母平肝潜阳、定惊明目，用于治疗头痛眩晕、烦躁失眠、肝热目赤、肝虚目昏，具有延迟白内障的形成、抗溃疡、抗氧化的作用。
白茅根：味甘，性寒，归肺经、胃经、膀胱经。白茅根凉血止血，清热利尿，用于治疗血热吐血、衄血、尿血、热病烦渴、黄疸、水肿、热淋涩痛、急性肾炎水肿，具有利尿、促凝血、增加免疫功能等作用。
本发明中药组合物使用方法：将本发明的中药组合物药水使用纱布或者纸膜浸湿后平整贴敷于面部皮肤，前一周每日使用1次，每次15分钟，第二周每周使用2-3次，每次15分钟。
本发明产生的技术效果：
本发明的抗菌美白中药组合物配伍合理，发明人通过优化中药的组分及含量配比，优选出了对抗菌和美白具有确切、显著的治疗效果的中药组合物处方。本发明的中药组合物具有修复皮肤屏障、促进伤口修复的功效，对于改善面部痤疮、面部皮炎瘙痒和面部色斑暗沉具有显著疗效。
具体实施方式
下面结合实施例对本发明作更进一步的说明，但本发明的实施方式不限于此。下述实施例中所使用的实验方法如无特殊说明，均为常规方法。
实施例1
称取千里光10g，龙胆草10g，羊乳30g，白蔹30g，白芨30g，积雪草10g，茯苓30g，薏苡仁30g，珍珠母30g，白茅根15g，将上述中药混合后加纯净水1500mL，浸泡30min，大火煮开后文火煎煮30min，将煎煮后的药液倒入容器中，药渣再加入纯净水1200mL，大火煮开后文火煎煮30min，将两次煎煮的药液合并，过160目筛，3000转离心5min，取上清液，浓缩制成浓度为0.33g/mL的中药提取液，置于4℃冰箱保存备用，即得本发明的中药组合物1。
实施例2
称取千里光30g，龙胆草30g，羊乳10g，白蔹10g，白芨30g，积雪草10g，茯苓30g，薏苡仁30g，珍珠母30g，白茅根15g，将上述中药混合后加纯净水1500mL，浸泡30min，大火煮开后文火煎煮30min，将煎煮后的药液倒入容器中，药渣再加入纯净水1200mL，大火煮开后文火煎煮30min，将两次煎煮的药液合并，过160目筛，3000转离心5min，取上清液，浓缩制成浓度为0.33g/mL的中药提取液，置于4℃冰箱保存备用，即得本发明的中药组合物2。
实施例3
称取千里光30g，龙胆草30g，羊乳30g，白蔹30g，白芨10g，积雪草10g，茯苓10g，薏苡仁30g，珍珠母30g，白茅根15g，将上述中药混合后加纯净水1500mL，浸泡30min，大火煮开后文火煎煮30min，将煎煮后的药液倒入容器中，药渣再加入纯净水1200mL，大火煮开后文火煎煮30min，将两次煎煮的药液合并，过160目筛，3000转离心5min，取上清液，浓缩制成浓度为0.33g/mL的中药提取液，置于4℃冰箱保存备用，即得本发明的中药组合物3。
实施例4
称取千里光30g，龙胆草30g，羊乳30g，白蔹30g，白芨30g，积雪草10g，茯苓30g，薏苡仁10g，珍珠母10g，白茅根15g，将上述中药混合后加纯净水1500mL，浸泡30min，大火煮开后文火煎煮30min，将煎煮后的药液倒入容器中，药渣再加入纯净水1200mL，大火煮开后文火煎煮30min，将两次煎煮的药液合并，过160目筛，3000转离心5min，取上清液，浓缩制成浓度为0.33g/mL的中药提取液，置于4℃冰箱保存备用，即得本发明的中药组合物4。
实施例5
称取千里光5g，龙胆草5g，羊乳30g，白蔹30g，白芨30g，积雪草5g，茯苓30g，薏苡仁30g，珍珠母30g，白茅根30g，将上述中药混合后加纯净水1500mL，浸泡30min，大火煮开后文火煎煮30min，将煎煮后的药液倒入容器中，药渣再加入纯净水1200mL，大火煮开后文火煎煮30min，将两次煎煮的药液合并，过160目筛，3000转离心5min，取上清液，浓缩制成浓度为0.33g/mL的中药提取液，置于4℃冰箱保存备用，即得本发明的中药组合物5。
试验例1、本发明中药组合物对B16黑色素瘤细胞的抑制作用
1、试验方法
在无菌条件下，将B16黑色素瘤细胞接种于含10％澳洲胎牛血清的RPMI-1640培养基中，于二氧化碳培养箱中37℃、5％CO2饱和湿度环境中培养，每天换液。当细胞生长至汇合度为80％-90％时，经0.25％胰蛋白酶消化传代，继续培养。每次实验取自同一传代细胞，初始接种细胞浓度为1×105个·mL-1。
取指数生长期的B16黑色素瘤细胞，经消化分散制备单细胞悬液，调整细胞密度，以每孔1×104个的细胞密度接种于96孔板，培养12h待细胞完全贴壁后更换新培养基，每孔加入100μL本发明实施例1-5制备的中药组合物稀释液(将实施例1-5中浓度为0.33g/mL的中药提取液用纯净水均稀释成浓度3.3mg/mL的中药组合物稀释液)，每个浓度设置10个复孔，对照组加入新鲜培养液培养24h后每孔加入1mg·mL-1MTT溶液10mL，37℃，5％CO2培养箱内培养避光孵育3-4h，弃去培养基和MTT，向各孔加入200μL的DMSO，以溶解残留的MTT，室温于摇床震荡10min。震荡混匀后用酶标仪测定各孔在492nm波长下测定吸光值。细胞增殖率按以下公式计算：细胞增殖率＝(实验孔OD-空白孔OD)/(对照组OD-空白孔OD)×100％。
2、试验结果
本发明各试验组中药组合物对B16黑色素瘤细胞增殖率的影响如下表1所示。
表1本发明中药对B16黑色素瘤细胞增殖率的影响
表1结果显示，本发明实施例1-5的中药组合物可显著抑制B12黑色素细胞的生长，证实本发明的中药组合物具有美白功效，且实施例1对细胞增殖的抑制作用明显强于实施例2-5组。
试验例2、本发明中药组合物对P.acnes诱导的小鼠炎症模型的作用
1、试验方法
选取一株P.acnes菌株，将菌种置于脑心浸液培养基中进行培养，培养条件为厌氧条件下，37℃恒温培养72小时，将培养后的细菌进行转种活化并使之增殖。收集细菌菌落并进行洗涤并过滤，最后用PBS溶液将P.acnes的菌液浓度调整为1×108CFU/20μl。
选取健康小鼠随机分为对照组、模型组和本发明实施例1-5组，每组10只。以戊巴比妥(45mg/kg)腹腔内麻醉小鼠，对照组在小鼠双侧内耳郭中央皮内注射PBS溶液20μL，模型组和本发明实施例1-5组在小鼠双侧内耳郭中央皮内注射上述P.acnes混悬液20μL。建模5天后实施例1-5组在小鼠耳郭处涂抹实施例1-5制备的中药组合物1-5(浓度均为0.33g/mL)，每次0.1mL，对照组和模型组在小鼠耳郭处涂抹等量的生理盐水，每天2次，连续给药15d，在末次给药24h后处死小鼠，收集小鼠血清，以ELISA法按照试剂盒的说明进行相应操作，对IL-1β和TNF-ɑ的水平进行检测。
2、试验结果
使用本发明各试验组中药组合物治疗后小鼠血清中IL-1β和TNF-ɑ含量如下表2所示。
表2本发明各试验组中药组合物对小鼠血清中IL-1β和TNF-ɑ水平影响
从上表2可知，与模型组小鼠相比，本发明实施例1-5组均可不同程度降低小鼠血清中IL-1β和TNF-ɑ水平，证实本发明中药组合物具有治疗痤疮的功效，且实施例1对痤疮的治疗效果明显优于实施例2-5组。
虽然已经对本发明的具体实施方案进行了描述，但是本领域技术人员应认识到，在不偏离本发明的范围或精神的前提下可以对本发明进行多种改变与修饰。因而，本发明意欲涵盖落在附属权利要求书及其同等物范围内的所有这些改变与修饰。
Claims (10)
1.一种抗菌美白的中药组合物，其特征在于，所述中药组合物由千里光、龙胆草、羊乳、白蔹、白芨、积雪草、茯苓、薏苡仁、珍珠母和白茅根制备而成。
2.根据权利要求1所述的中药组合物，其特征在于，所述中药组合物由10-50重量份千里光、10-50重量份龙胆草、10-50重量份羊乳、10-50重量份白蔹、10-50重量份白芨、10-50重量份积雪草、10-50重量份茯苓、10-50重量份薏苡仁、10-50重量份珍珠母和10-50重量份白茅根制备而成。
3.根据权利要求2所述的中药组合物，其特征在于，所述中药组合物由10-30重量份千里光、10-30重量份龙胆草、10-30重量份羊乳、10-30重量份白蔹、10-30重量份白芨、10-30重量份积雪草、10-30重量份茯苓、10-30重量份薏苡仁、10-30重量份珍珠母和10-30重量份白茅根制备而成。
4.根据权利要求3所述的中药组合物，其特征在于，所述中药组合物由10-20重量份千里光、10-20重量份龙胆草、20-30重量份羊乳、20-30重量份白蔹、20-30重量份白芨、10-20重量份积雪草、20-30重量份茯苓、20-30重量份薏苡仁、20-30重量份珍珠母和10-20重量份白茅根制备而成。
5.根据权利要求4所述的中药组合物，其特征在于，所述中药组合物由10重量份千里光、10重量份龙胆草、30重量份羊乳、30重量份白蔹、30重量份白芨、10重量份积雪草、30重量份茯苓、30重量份薏苡仁、30重量份珍珠母和15重量份白茅根制备而成。
6.根据权利要求1-5任一项所述的中药组合物，其特征在于，所述中药组合物进一步包括药学上可接受的辅料。
7.根据权利要求1-5任一项所述的中药组合物，其特征在于，所述中药组合物的剂型为液体制剂。
8.权利要求1-7任一项所述中药组合物的制备方法，其特征在于，所述制备方法包括以下步骤：
(1)称取处方量的千里光、龙胆草、羊乳、白蔹、白芨、积雪草、茯苓、薏苡仁、珍珠母和白茅根，将上述中药混合后加入中药材重量4-8倍的纯净水，浸泡15-60min，大火煮开后文火煎煮20-40min；
(2)将煎煮后的药液倒入容器中，药渣再加入4-6倍重量的纯净水，大火煮开后文火煎煮20-40min；
(3)将两次煎煮的药液合并，过滤，离心取上清液，浓缩，即得。
9.权利要求1-7任一项所述中药组合物在制备抗菌药物中的应用。
10.权利要求1-7任一项所述中药组合物在制备具有美白功效的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310643014.4A CN116440222B (zh) | 2023-06-01 | 2023-06-01 | 一种抗菌美白的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310643014.4A CN116440222B (zh) | 2023-06-01 | 2023-06-01 | 一种抗菌美白的中药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116440222A true CN116440222A (zh) | 2023-07-18 |
| CN116440222B CN116440222B (zh) | 2024-04-23 |
Family
ID=87130407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310643014.4A Active CN116440222B (zh) | 2023-06-01 | 2023-06-01 | 一种抗菌美白的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116440222B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102440942A (zh) * | 2010-10-13 | 2012-05-09 | 黄军 | 中药去痘霜 |
| CN103211748A (zh) * | 2013-04-24 | 2013-07-24 | 朱珠 | 一种天然美白薏米粉及其制备方法和应用 |
| CN114748407A (zh) * | 2022-05-12 | 2022-07-15 | 浙江中医药大学附属第二医院 | 一种美白祛痘的中药面膜 |
-
2023
- 2023-06-01 CN CN202310643014.4A patent/CN116440222B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102440942A (zh) * | 2010-10-13 | 2012-05-09 | 黄军 | 中药去痘霜 |
| CN103211748A (zh) * | 2013-04-24 | 2013-07-24 | 朱珠 | 一种天然美白薏米粉及其制备方法和应用 |
| CN114748407A (zh) * | 2022-05-12 | 2022-07-15 | 浙江中医药大学附属第二医院 | 一种美白祛痘的中药面膜 |
Non-Patent Citations (2)
| Title |
|---|
| 李翠云;曹兰秀;: "《普济方》痤疮外治方白色药物应用浅析", 现代中医药, vol. 36, no. 04, 10 July 2016 (2016-07-10), pages 64 - 67 * |
| 杨岚;肖玮;江鹤灵;: "中医内外结合辨证施治面部色素沉着疗效观察", 中国美容医学, vol. 22, no. 11, 15 June 2013 (2013-06-15), pages 1222 - 1225 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116440222B (zh) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN104740541B (zh) | 一种保肝解毒恢复肝功能的保健中药粉 | |
| CN104739925A (zh) | 一种治疗痤疮的组合物及其制备方法 | |
| CN103393919A (zh) | 祛疤痕、痘印的中药软膏及其制备方法 | |
| CN102247562A (zh) | 一种治疗痤疮的中药配方 | |
| CN105708970B (zh) | 一种具有降血糖功能的保健食品 | |
| CN105902475B (zh) | 一种玫瑰花蛋清面膜及其制备方法 | |
| CN104873446A (zh) | 一种含肉桂油的牙膏 | |
| CN104323965A (zh) | 一种美容护肤用中药组合物 | |
| CN116440222B (zh) | 一种抗菌美白的中药组合物 | |
| CN114748407B (zh) | 一种美白祛痘的中药面膜 | |
| CN105999105A (zh) | 一种治疗褥疮和糖尿病溃烂的中药组合物及其制备方法 | |
| CN108815015A (zh) | 一种眼膜及其生产工艺 | |
| CN106860814B (zh) | 一种改善女性尿频、尿失禁的保健食品组合物及其制备方法和应用 | |
| CN104825905A (zh) | 一种治疗输血反应的中药制剂及其制备方法 | |
| CN108096506A (zh) | 一种祛疣中药植物提取液及其制备方法 | |
| CN103690811A (zh) | 一种降血压、预防头昏眼花的中药口服液及其制备方法 | |
| CN107823293A (zh) | 治疗口腔溃疡的瑶医外用散剂及其制备方法 | |
| CN102274420A (zh) | 一种治疗痤疮的中药组合物 | |
| CN105395943A (zh) | 一种具有减肥功效的芦荟组合物及其制备方法 | |
| CN105031170A (zh) | 一种保健足浴粉及其制备方法 | |
| CN110694039A (zh) | 一种减肥中药组合物及其制备方法 | |
| CN104606501B (zh) | 一种治疗湿热型腹部手术后尿潴留的中药 | |
| CN108815082A (zh) | 一种面膜及其生产工艺 | |
| CN105169152A (zh) | 一种皮肤止痒洗液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |